Berenice Campa-Cordoba

Dr. Berenice Campa-Cordoba

Biobanco Nacional de Demencias
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Luis O. Soto-RojasLuis O. Soto-Rojas
Luis O. Soto-Rojas
MPMar Pacheco-Herrero
Mar Pacheco-Herrero
PMPaola A. Martínez-Gómez
Paola A. Martínez-Gómez
BCBerenice Campa-Cordoba
Berenice Campa-Cordoba
RARicardo Apátiga-Pérez
Ricardo Apátiga-Pérez
José Luna-MuñozJosé Luna-Muñoz
José Luna-Muñoz
Alzheimer’s disease (AD) is the most common neurodegenerative disease worldwide. Histopathologically, AD presents with two hallmarks: neurofibrillary tangles (NFTs), and aggregates of amyloid β peptide (Aβ) both in the brain parenchyma as neuritic plaques, and around blood vessels as cerebral amyloid angiopathy (CAA). According to the vascular hypothesis of AD, vascular risk factors can result in dysregulation of the neurovascular unit (NVU) and hypoxia. Hypoxia may reduce Aβ clearance from the brain and increase its production, leading to both parenchymal and vascular accumulation of Aβ. An increase in Aβ amplifies neuronal dysfunction, NFT formation, and accelerates neurodegeneration, resulting in dementia. In recent decades, therapeutic approaches have attempted to decrease the levels of abnormal Aβ or tau levels in the AD brain. However, several of these approaches have either been associated with an inappropriate immune response triggering inflammation, or have failed to improve cognition. Here, we review the pathogenesis and potential therapeutic targets associated with dysfunction of the NVU in AD.

Verified
Journal Article
Open access
PDF file
Luis O. Soto-RojasLuis O. Soto-Rojas
Luis O. Soto-Rojas
BCBerenice Campa-Cordoba
Berenice Campa-Cordoba
Charles HarringtonCharles Harrington
Charles Harrington
ASAndres Salas-Casas
Andres Salas-Casas
MHMario Hernandes
Mario Hernandes
José Luna-MuñozJosé Luna-Muñoz
José Luna-Muñoz
Alzheimer’s disease (AD) is a neurodegenerative disease, characterized histopathologically by intra-neuronal tau-related lesions and by the accumulation of amyloid β-peptide (Aβ) in the brain parenchyma and around cerebral blood vessels. According to the vascular hypothesis of AD, an alteration in the neurovascular unit (NVU) could lead to Aβ vascular accumulation and promote neuronal dysfunction, accelerating neurodegeneration and dementia. To date, the effects of insoluble vascular Aβ deposits on the NVU and the blood–brain barrier (BBB) are unknown. In this study, we analyze different Aβ species and their association with the cells that make up the NVU. We evaluated post-mortem AD brain tissue. Multiple immunofluorescence assays were performed against different species of Aβ and the main elements that constitute the NVU. Our results showed that there are insoluble vascular deposits of both full-length and truncated Aβ species. Besides, insoluble aggregates are associated with a decrease in the phenotype of the cellular components that constitute the NVU and with BBB disruption. This approach could help identify new therapeutic targets against key molecules and receptors in the NVU that can prevent the accumulation of vascular fibrillar Aβ in AD.

15 June 2020 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
ARAldelmo Emmanuel Reyes-Pablo
Aldelmo Emmanuel Reyes-Pablo
BCBerenice Campa-Cordoba
Berenice Campa-Cordoba
NLNabil Itzi Luna-Viramontes
Nabil Itzi Luna-Viramontes
MOMiguel Angel Ontiveros-Torres
Miguel Angel Ontiveros-Torres
IVIgnacio Villanueva
Ignacio Villanueva
José Luna-MuñozJosé Luna-Muñoz
José Luna-Muñoz
We recently developed the National Dementia Biobank in México (BioBanco Nacional de Demencias, BND) as a unit for diagnosis, research, and tissue transfer for research purposes. BND is associated with the Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de Mexico (UNAM), Mexico. The donation of fluids, brain, and other organs of deceased donors is crucial for understanding the underlying mechanisms of neurodegenerative diseases and for the development of successful treatment. Our laboratory research focuses on 1) analysis of the molecular processing of the proteins involved in those neurodegenerative diseases termed tauopathies and 2) the search for biomarkers for the non-invasive and early diagnosis of Alzheimer’s disease.